Evidence map›Paper›PMID 29048621›Full record

ArticleOncology reports2017

Irisin reverses the IL-6 induced epithelial-mesenchymal transition in osteosarcoma cell migration and invasion through the STAT3/Snail signaling pathway.

Gang Kong, Yunpeng Jiang, Xiujiang Sun, Zhilin Cao, Guodong Zhang, Zhongyuan Zhao, Yong Zhao, Qian Yu, Gong Cheng

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Mechanisms Underlying the Rarity of Skeletal Muscle Cancers.International journal of molecular sciences · 2024
    Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Gang KongDepartment of Orthopaedics, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China.
Yunpeng JiangDepartment of Orthopaedics, Qilu Hospital of Shandong University, Jinan, Shandong 250000, P.R. China.
Xiujiang SunDepartment of Orthopaedics, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China.
Zhilin CaoDepartment of Orthopaedics, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China.
Guodong ZhangDepartment of Orthopaedics, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China.
Zhongyuan ZhaoDepartment of Orthopaedics, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China.
Yong ZhaoDepartment of Orthopaedics, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China.
Qian YuDepartment of Orthopaedics, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China.
Gong ChengDepartment of Orthopaedics, Yantaishan Hospital, Yantai, Shandong 264001, P.R. China.
Yantaishan Hospital · CNQilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a novel discovered myokine, irisin is considered to be a promising candidate for the treatment of metabolic disorders and cancer. However, little is known about the anti-metastasic effect of irisin on osteosarcoma cells and its underlying mechanisms. In the present study, we aimed to explore the effect of irisin on the migration and invasion of osteosarcoma cells and the underlying mechanisms involved. Viability and proliferation of osteosarcoma cells were examined by MTT assay. Then, by using scratch wound healing assay and Transwell assays, we evaluated migratory and invasive ability of the cells, respectively. Moreover, the expression of epithelial-to-mesenchymal transition (EMT) markers were determined by qPCR, western blot and immunofluorescence staining after treatment with IL-6 and irisin. Furthermore, the expression of ERK, p38, STAT3 and Snail were detected by western blot analysis. Finally, an inhibitor of STAT3, WP1066 was applied to testify the effect of irisin on the expression of EMT markers and Snail. It was found that irisin treatment significantly suppressed the proliferation, migration and invasion of osteosarcoma cells. Furthermore, irisin reversed the IL-6-induced epithelial‑mesenchymal transition (EMT) in osteosarcoma cells by regulating the expression of E-cadherin, N-cadherin, vimentin, fibronectin, MMP-2, MMP-7 and MMP-9. In addition, irisin suppressed the IL-6-activated phosphorylation of STAT3 and the expression of Snail in osteosarcoma cells. Finally, blockade of STAT3 by WP1066 (a STAT3 inhibitor) further enhanced the effect of irisin on the EMT and Snail expression in osteosarcoma cells. Collectively, our findings revealed that irisin may play a critical role in the IL-6-induced EMT of osteosarcoma cells via the STAT3/Snail signaling pathway.

Indexed as

Signal TransductionBone NeoplasmsCell Line, TumorCell MovementCell ProliferationCell SurvivalEpithelial-Mesenchymal TransitionFibronectinsGene Expression Regulation, NeoplasticHumansInterleukin-6Neoplasm InvasivenessOsteosarcomaPyridinesSnail Family Transcription FactorsSTAT3 Transcription FactorFibronectinsFNDC5 protein, humanIL6 protein, humanInterleukin-6PyridinesSnail Family Transcription FactorsSTAT3 protein, humanSTAT3 Transcription FactorTyrphostinsWP1066

Identifiers

PMID29048621
PMCPMC5780017
OpenAlexW2755398419

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.